Glucocorticoids, prescribed for their anti-inflammatory and immunosuppressive effects, are linked to psychiatric side effects, including corticosteroid-induced psychosis. This condition may manifest as affective, organic, or cognitive disturbances, and although the exact pathophysiology is not fully understood, it is believed that corticosteroids impact the hippocampus and hypothalamic-pituitary-adrenal axis, causing neuropsychiatric changes. This report presents two cases of psychosis following corticosteroid use: a 59-year-old man with rheumatoid arthritis and a 62-year-old woman with asthmatic bronchitis. Both cases demonstrated rapid symptom improvement with antipsychotic treatment, emphasizing the need for early intervention. Despite the unclear pathophysiology, corticosteroid-induced psychosis generally has a positive prognosis when promptly managed with drug discontinuation and pharmacological treatment.
1 October 2015 in Journal of Clinical Psychopharmacology
Introduction. The brain-derived neurotrophic factor (BDNF) is a neurotrophin that has been linked to the schizophrenia neurodevelopmental hypothesis. Several studies confirm that the BDNF levels in first-episode psychosis (FEP) are lower than in healthy controls (HC). However, data about evolution of BDNF levels after a FEP and about the prognostic value of these levels are controversial. Method. Serum BDNF levels at admission of 28 inpatients with FEP were compared with 28 HC. BDNF was also measured at discharge, three, six, nine and twelve months. BDNF levels are presented in ng/ml. We looked for correlation of BDNF levels with the psychotic symptomatology measured with the Positive and Negative Syndrome Scale (PANSS) and also the prognostic value of basal levels was evaluated to predict poor functionality (measured by the Global Assessment of Functioning) and/or relapse, as well as the subsequent diagnosis of a chronic psychotic disorder. Results. At admission, patients BDNF levels were significantly lower than HC levels (18.52 +/- 4.51 vs. 26.55 +/- 3.22, p<0.001). At discharge FEP levels increase until HC levels (25.95 +/- 3.96 vs. 26.55 +/- 3.22, p=0,539). Upon the following determinations, BDNF FEP levels decreased, reaching the admission values, and being significantly lower than the HC and the levels at discharge (patients: three months: 19.68 +/- 3.88; six months: 19.02 +/- 4.13; nine months: 17.64 +/- 5.24; twelve months: 17.51 +/- 3.45 vs. HC: 26.55 +/- 3.22, all p<0.001). A negative correlation was found between admission BDNF levels and the PANSS negative symptoms subscale score with a trend towards significance (r=-0.303, p=0.093). BDNF levels at admission of patients with por functionality and/or relapse at 12 months were lower than BDNF levels of patients with goof functionality and without relapse, this difference had a trend towards significance. (15.38 +/- 4.72 vs. 19.57 +/- 4.06; p=0.071). We didn't found differences between basal BDNF levels of patients who developed a chronic psychotic disorder and patients who didn't. Conclusions. Our results reinforce the neurotrophin hypothesis. Basal levels (at diagnosis) of a FEP could predict the prognosis in terms of functionality and risk of relapse in the first year.
1 November 2024 in Journal of Clinical Psychopharmacology
Fahr’s disease (FD) is a rare disorder consisting of bilateral and symmetrical calcium deposits in basal ganglia and cerebral cortex. These lesions are associated with neurological and psychiatric symptoms such as a rigid hypokinetic syndrome, mood disorders and memory and concentration abnormalities. It can be idiopathic or secondary to endocrine disorders, infectious diseases or mitochondrial myopathies. To highlight the importance of considering organic causes when evaluating patients presenting atypical psychiatric symptoms and claim the role of neuroimaging. Case report and non-systematic review of literature: sources obtained from Pubmed database. A 69-year-old man, native of Syracuse (Italy), was admitted to the Psychiatry Unit in February 2022 presenting behavioural disturbances and irritability. In July 2021 he presented the same symptoms, being mistakenly diagnosed with Bipolar Disease type I. He has no previous psychiatric history. He started with changes in his personality, short-term memory loss, aggressiveness and disorganized behaviour at the age of 66. At admission he was talkative and hyperfamiliar, presenting delusions of grandiosity, exalted affectivity and insomnia. Neurological examination showed short-term memory problems, signs of frontal disinhibition and abnormal glabellar tap sign. Blood tests, CT brain and MRI were performed to rule out organic underlying causes. Neuro-imaging found bilateral and symmetric calcifications in globus pallidus, thalamus and corpus striatum, in favour of FD. Secondary causes (abnormalities in the PTH, vitamin disorders and infectious diseases such as HIV, brucellosis or neurosyphilis) where discarded, allowing us to conclude it was probably a primary case of FD. Valproate was started as a mood stabilizer and anticonvulsant. Genetic tests were indicated. FD should be considered as a differential diagnosis in the evaluation of psychiatric symptoms, especially when atypical and/or presented with neurological symptoms. The role of neuro-imaging is essential. None Declared